※Pluristem 21時間前:”All of us from Pluristem would like to wish you a Happy New Year 2019. We look forward to a year of making new strides in Cell Therapy.” (1/2)
※Vectura: ”Pre-close trading update confirms good progress against 2018 goals.” (1/3) Chippenham, UK - 03 January 2019: Vectura Group today announces an unaudited 2018 pre-close trading update. The Group expects revenue to be in line with, and EBITDA to be materially above, current market consensus expectations. Vectura will report its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019. Highlights: Vectura revenues continue to grow in line with expectations, underpinned by positive in-market sales performance of: ・Ultibro total in-market sales1 were up 12.2% for the 12 month period to September 2018 - Europe +9.7%, Japan -0.8% and ROW +27.3% - all at CER compared to the 12 months to September 2017. James Ward-Lilley, Chief Executive Officer of Vectura, commented: "Vectura has made good progress in the year with positive top line performance, pipeline evolution aligned with our refocused investment strategy, and strong operational execution. We look forward to 2019 with key news flow on VR315, partnering of VR647, further disclosure and momentum on our new Vectura Enhanced Nebulised assets as well as Phase III results from QVM149, our inhaled triple combination therapy for asthma, partnered with Novartis." 0044山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/03(木) 22:01:05.67ID:QFjXZRr30 Sosei Heptares_HP: Scientific and Medical Events: up: ※”Cambridge New Therapeutics Forum (CamNTF) February Meeting” by CamNTF Organising Committee Granta Park. (2/13 17:30-20:30) Description: ・Host: Heptares. Andy Dore. ・Date: Wednesday, 13 February 2019 ・Location: Granta Centre, Granta Park, UK Programme: ・17:30 - Arrival, Registration, Tea & Coffee. ・18:00 - Welcome. ・18:10 - Prof Richard Henderson, Nobel Laureate, CH, FRS, FMedSci, HonFRSC, MRC Laboratory of Molecular Biology, Cambridge. ・18:35 - Dr Pamela Williams, Astex Pharmaceuticals. ・18:55 - Dr Stacey Southall, Sosei-Heptares. ・19:10 - Networking and Refreshments. ・20:00 - Meeting close. 0045山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/03(木) 22:03:36.74ID:QFjXZRr30 ※Sosei Heptares Events: ・・・ ※第37回 J.P.モルガン ヘルスケア カンファレンス:Sosei Heptares、MiNA Therapeutics. (1/7-10) ※American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium 2019: MiNA Therapeutics. (1/17-19) ※Pfizer Quarterly Corporate Performance - Fourth Quarter 2018. (1/29) ※R&D支援センター セミナー:「ペプチド医薬品原薬の製造プロセス開発における注意点」〜合成方法・分析方法・精製方法・スケールアップ…各工程における留意点とは〜 講師:JITSUBO(株) 研究開発部部長 山ア貴史 (1/30 12:30-16:30) ※Novartis Q4 and Full Year Results 2018 and Annual Report 2018 Publication. (1/30) ※大日本住友製薬 2019年3月期第3四半期決算発表 (2019/1/31) ※Cambridge New Therapeutics Forum (CamNTF) February Meeting (2/13 18:00-20:00): (Host: Heptares. Location: Granta Park): Richard Henderson, MRC LMB (2/13 18:10 Presenting), Stacey Southall, Sosei Heptares. (2/13 18:55 Presenting) ※あすか製薬 平成31年3月期第3四半期決算 (2月上旬) ※AstraZeneca Full-Year 2018 Results. (2/14) ※Sosei Group 2018年12月期決算発表 (2月中旬) ※PeptiDream平成31年6月期第2四半期決算発表 (2月中旬) ※SMi's 10th Annual RNA Therapeutics 2019, London: ”Small Activating RNA - from Bench to Bedside”: David Blakey, Chief Scientific Officer, MiNA Therapeutics. (2/21 14:20 Presenting) ※Sosei Group定時株主総会 (3月) ※Fragments 2019: 7th RSC-BMCS Fragment-based Drug Discovery Meeting, Cambridge: "Enabling FBDD for GPCRs with Protein Engineering and Biophysics": Rob Cooke, Sosei Heptares, . (3/26 14:15 Presenting) ※American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta: MiNA Therapeutics. (3/29-4/3) ※30th Symposium on Medicinal Chemistry in Eastern England: "Application of Structure-Based Drug Discovery to G Protein-Coupled Receptors": Miles Congreve, Sosei Heptares. (5/2 16:05 Presenting) ※TIDES: Oligonucleotide and Peptide Therapeutics 2019, San Diego: MiNA Therapeutics Translation and Innovation Hub. (5/20-23) ※American Society of Clinical Oncology (ASCO) Annual Meeting 2019, Chicago: MiNA Therapeutics. (5/31-6/4) ※Neuroscience In Discovery & Development Congress 2019, Berlin: Speakers: Pradeep Nathan, Vice President CNS Clinical Development & Head of Experimental Medicine, Sosei Heptares. (6/11-12). ※2nd RSC Anglo-Nordic Medicinal Chemistry Symposium, Denmark: "Structurally Enabled Discovery of Innovative Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists": Steve Watson, Sosei Heptares. (6/11-14). ・・・ 0046山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/03(木) 22:34:17.99ID:jN6opfho0 ブリストルマイヤーズがセルジーンを買収 ここも早く買収されてもらいたいわ 株価1500円以上で 0047山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/03(木) 22:36:30.15ID:jN6opfho0 720億ドルって桁違いの買収金額だな 仮に、そーせいが株価1500円で買収されても時価総額にしたら1144億円ってゴミみたいな価値だな 何がメガファーマだよおうこら 0048山師さん@トレード中 (ワッチョイ 0b71-xhm2 [218.110.108.83])2019/01/03(木) 23:20:30.68ID:oz3mtJFK0 セルジーンってレセプトスを買収した会社だよな 買収金額同じくらいの金額だな 0049山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/03(木) 23:46:03.15ID:QFjXZRr30 Pluristem update: ・・・ ※Pluristem: U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia. Pluristem enters into agreement with WideTrial Inc. to conduct the program. WideTrial will purchase PLX-PAD cell products from Pluristem. (10/16) ※Pluristem: Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions(11/10). also present at the BioEurope(11/6), Annual Vascular Interventional Advances(11/7) and Cell and Gene Therapy Manufacturing conferences(11/15), all held in November. (10/18) ※Vascular Interventional Advances (VIVA) Conference 2018, Las Vegas: Overview of its off-the-shelf, placenta-derived cell therapy technology and development plans for its lead cell therapy candidate, PLX-PAD, for the treatment of peripheral artery disease (PAD): Pluristem. (11/7 Presented) ※Pluristem Reports Fiscal 2019 First Quarter Results: Forward - Looking Statements: our expectations regarding; Sosei CVC for the clinical development and commercialization of Pluristem’s PLX-PAD cell therapy product in Japan, the plan to enter into definitive agreements. (11/8) ※American Heart Association (AHA) Scientific Sessions 2018, Chicago: New Trials in Cardiovascular Care: "A Phase II Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogenic PLX-PAD Cells for the Treatment of Subjects with Intermittent Claudication": Pluristem. (11/10 Presented) ※Pluristem: "New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation". -Additional data from Pluristem’s Phase II IC study were presented at the 2018 American Heart Association Scientific Sessions- (11/12) ※Cell and Gene Therapy Manufacturing conference, London: "It May Sound Crazy But… Addressing Scalability at the Beginning NOT the End": Lior Raviv, Vice President of Development, Pluristem. (11/15 Presented) ※Pluristem Presentations: Phase II IC Results - American Heart Association Conference - Presentation November 2018. (11/15up) , Company Presentation July 2018→"Company Presentation November 2018". (11/15update) ※Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematology’s (ASH) Annual Meeting. Clinical data from the first cohort of Phase I study for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation. (11/28) 0050山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/03(木) 23:46:29.29ID:QFjXZRr30 ※Pluristem: The Real Impact of PAD - Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease. Today announced that it will host a Key Opinion Leader (KOL) meeting on Peripheral Artery Disease (PAD) on December 14, 2018 in New York City. (11/29) ※Pluristem_HP Events update: American Society of Hematology (ASH), San Diego: December 1-4, 2018. ・Cell Therapy Manufacturing & Gene Therapy Congress, Netherlands: December 4-5, 2018. ・KOL Breakfast on Peripheral Artery Disease (PAD), New York: December 14, 2018. (12/3up) ※Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the ASH Annual Meeting: Primary safety endpoint met in first cohort with early signals of efficacy in improving blood counts. Enrollment in the second cohort currently underway. (12/3) ※Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.. "Pluristem’s best-in-class cellular thawing device is a perfect complement to Chart’s portfolio of solutions." (12/4) ※Pluristem: Pluristem in the Media: "Cell therapy produced from the plurality of the Israeli company Pluristem". Cell therapy. Before the news, Channel 13, December 2018. ttps://youtu.be/c0veRDrSH7s (12/11) ※Pluristem: "Reminder- Pluristem Therapeutics to Host Key Opinion (KOL) Leader Meeting on Peripheral Artery Disease Tomorrow". Discuss the current treatment landscape and unmet medical needs, the economic impact, and potential market opportunities for treating patients with PAD. (12/13) ※Pluristem Presentations: "Company Presentation PAD KOL Day- December 14, 2018". ttp://www.pluristem.com/wp-content/uploads/2016/04/Pluristem-December-14-2018_PAD-DAY_all-presentations.pdf (12/16up) ※Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD): Presentations underscore significant need for new PAD treatment approaches and the potential of cell therapy to improve patient outcomes while reducing healthcare costs. (12/17) ※Pluristem: ”All of us from Pluristem would like to wish you a Happy New Year 2019. We look forward to a year of making new strides in Cell Therapy.” (2019/1/2) ↓ 0051山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/03(木) 23:47:00.33ID:QFjXZRr30 ※Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome. (2019/1/3) HAIFA, Israel, Jan. 03, 2019 -- Pluristem Therapeutics Inc., a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced it has concluded a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the ongoing development of PLX-R18 for the treatment of Acute Radiation Syndrome (ARS). The FDA provided Pluristem with feedback on the progress and data collected on PLX-R18 to date and gave guidance towards advancing the development of PLX-R18 with respect to the treatment of ARS. The meeting also included representatives from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the U.S. Biomedical Advanced Research and Development Authority (BARDA). “We are pleased to have completed a positive meeting with the FDA and U.S. government agencies representatives, which we believe has provided us with a clear and efficient path towards advancing the development of PLX-R18, targeting approval in the treatment of ARS,” said Mr. Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “ For several years, we have successfully cooperated with the NIAID, which has supported and conducted studies of PLX-R18 in ARS. These studies demonstrated PLX-R18 potential to increase survival rates after radiation exposure, as well as protect and regenerate the bone marrow’s ability to produce blood cells, crucial for victims exposed to high levels of radiation. We are pleased to see interest from key governmental agencies such as NIAID, the U.S Department of Defense and BARDA in our novel regenerative medical countermeasure for radiation injuries and look forward to potentially supporting such medical needs of the U.S. government.” PLX-R18 has been studied in Phase I and II-equivalent studies conducted and funded by NIAID via the FDA Animal Rule Pathway. Results from these studies showed that PLX-R18 supports the recovery of the bone marrow and increases survival rates. PLX-R18 has been granted an Investigational New Drug application (IND) and an orphan drug designation by the FDA for the treatment of ARS. ARS involves severe, potentially lethal damage to the bone marrow’s ability to produce blood cells, as well as to other systems and organs. Severe damage to bone marrow renders victims vulnerable to life-threatening hemorrhage, infection and anemia. 0052山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/03(木) 23:56:51.14ID:QFjXZRr30 ・・・ 0053山師さん@トレード中 (ワッチョイW 2ff1-yq5T [222.5.216.180])2019/01/04(金) 00:15:36.73ID:0JQv59TN0 今年は3倍になるよ 予言しとくから 0054山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/04(金) 00:21:57.17ID:fXexs35I0 昨年の年初にtakも馬鹿げた事を言ってて気づけば三分の一w あいつもえれー含み損だろうな
サクラ大戦きてんね( ^ω^) 哲人投資家・大重さんが、1552国際のETF VIX短期先物指数で、約40%の利益を得たようだ。 0063山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/04(金) 06:00:04.25ID:0W2Z7ElX0 ※Pluristem 3時間前:"We’re pleased to announce the completion of a positive meeting with the US_FDA on a development plan for our potential AcuteRadiationSyndrome treatment. Read the full pressrelease." (1/3) ※Pluristem 2時間前:"Our co-CEO, Zami Aberman, will discuss Pluristem's work at the BioCentury Power Breakfast Roundtable next Tues, January 8 during JP Morgan Healthcare Conference in San Francisco." (1/3) 0064山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/04(金) 06:00:23.80ID:0W2Z7ElX0 ・・・ 0065山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/04(金) 06:00:50.61ID:0W2Z7ElX0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 ・・・ ※Sosei Heptares:「第7回みずほバイオカンファレンス(12/13) プレゼン資料」2019年度の戦略方針:当社の成長戦略:世界をリードする技術を基盤とした、成功の為の2つの柱。提携を増強し、研究開発投資を厳選することで、早期黒字化を目指す。2019年にさらなる提携実現を目指す。(12/17up) ※British Pharmacological Society's Pharmacology 2018: "Structural Insights into Allosteric Modulation of GPCRs": Dr Christine Oswald, Sosei Heptares. (12/18 Presented) ※ClinicalTrials(NCT03379233): Ultibro(Phase3): "Concept2 Inhaler: Digital Adherence System": A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence. Record Verification December. (12/18update) ※ClinicalTrials(NCT03592862): Phase 2, A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies (DLB). Record Verification: December. Study Start (Change): "April 2019" (12/18update) ※Sosei Heptares_HP:知識:開発:「健康な治験者を対象とした選択的M1受容体作動薬HTL0018318の単回および複数回投与における安全性、忍容性、薬物動態について」(ACNP Presented: 12/12) これらの良好な安全性及び薬物動態データはHTL0018318の開発を後押しするもの。(12/19up) ※MiNA Therapeutics:"MiNA Therapeutics Announces Enrolment of Patients in Expansion of Phase Ib Trial Evaluating MTL-CEBPA in Combination with Sorafenib". "Excited to launch the next stage of the OUTREACH clinical trial in liver cancer". (12/19) ※Sosei Heptares:「進行肝がん患者を対象にした小分子活性化RNA肝がん治療候補薬MTL-CEBPAとソラフェニブとの併用を評価する第Tb 相臨床試験の患者登録開始を発表」MTL-CEBPAとソラフェニブとの併用時の評価は進行肝がん患者38人を対象にした MTL-CEBPA単剤での評価に続くもの。(12/20) ※Sosei Heptares_HP:企業情報:経営陣:シニアマネジメント:「ジェイムス・テイラー:シニア・ヴァイス・プレジデント 事業開発」追加。豊富なビジネス戦略の経験と、医薬品、バイオテクノロジー分野においての確固たる実績を持つ事業開発部のシニアヴァイスプレジデント。(12/20up) ※British Pharmacological Society's Pharmacology 2018: "Trends and Innovation in Drug Discovery at Heptares Therapeutics": Dr Lisa Stott, Sosei Heptares; Dr Matt Barnes, Sosei Heptares. (12/20 Presented) ※国際特許出願(Heptares):Pharmaceutical Compounds (WO/2018/229511 A1). (12/20公開) ※米国特許出願(Heptares):Pharmaceutical Compounds (US20180362507 A1). (12/20公開) 0066山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/04(金) 06:01:15.78ID:0W2Z7ElX0 ※医薬品医療機器総合機構(Pmda):医療用医薬品添付文書情報(更新):口腔粘膜付着型 口腔咽頭カンジダ症治療剤「オラビ錠口腔用50mg(ORAVI Mucoadhesive Tablets 50mg)」ミコナゾール付着錠:製造販売元:そーせい/販売元:富士フイルム富山化学 [販売開始年月2019年2月]。(12/21掲載) ※ClinicalTrials(NCT03785054): "Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242". Actual Study Start: "2018/11/14", Estimated Primary Completion: "2019/7/15", Estimated Study Completion: "2019/8/2". (New Trial Record 12/24up: "Recruiting") ※Sosei Heptares:「サンフランシスコで開催の第37回 J.P.モルガン・ヘルスケア・カンファレンスに参加」。2019年1月7日(米国時間)、当社CFOのクリス・カーギルがプレゼンテーションを行います。プレゼンテーションの様子はライブ配信され、アクセスできます(英語のみ)。(12/27) ※米国特許出願(Heptares):Orexin Receptor Antagonists (US20180370961 A1). (12/27公開) ※Sosei Heptares:「新年挨拶 代表執行役会長兼CEO 田村眞一」本日から会長兼任の社長に復帰。ブランドもSosei Heptaresと刷新し、全社一体となってグローバルなビジネス展開を図っていきます。舵を切り直して新たなリーダーシップの下に早急に収益体質の改善を目指します。(2019/1/1) ・StaR技術の可能性を最大限に追及してマネタイズ。同時に日常的に他の創薬技術との相乗効果も検討・導入して自社の創薬エンジンを世界のトップレベルに維持。全社を挙げて結果責任を取れるSosei Heptaresにして参ります。 ※米国特許(Heptares):CGRP Receptor Antagonists (US Patent 10166226 B2). (1/1公開) ※米国特許(Heptares):Muscarinic Agonists (US Patent 10167272 B2). (1/1公開) ※米国特許(Heptares):Spirocyclic Compounds as Agonists of the Muscarinic M1 Receptor and/or M4 Receptor (US Patent 10167284 B2). (1/1公開) ※Vectura: Pre-Close Trading Update Confirms Good Progress Against 2018 Goals: "Highlights: Ultibro total in-market sales were up 12.2% for the 12 month period to September 2018 - Europe +9.7%, Japan -0.8% and ROW +27.3% - all at CER compared to the 12 months to September 2017." (1/3) ・James Ward-Lilley, CEO of Vectura, Commented: "We look forward to 2019 with key news flow, further disclosure on Phase III results from QVM149, our inhaled triple combination therapy for asthma, partnered with Novartis." ・・・ ※第37回 J.P.モルガン ヘルスケア カンファレンス(1/7-10):Sosei Heptares(1/7 9:30 Presenting), Novartis(1/7 Presenting), Allergan(1/7 15;30 Presenting), Vectura(1/10 9:30 Presenting), MiNA Therapeutics. ※Allergan Q4 2018 Allergan plc Earnings Conference Call. (1/29) ※Novartis Q4 and Full Year Results 2018 and Annual Report 2018 Publication. (1/30) ・・・ 0067山師さん@トレード中 (ワッチョイ 5bc3-r5Pt [202.124.48.6 [上級国民]])2019/01/04(金) 06:02:17.83ID:0W2Z7ElX0 ※SOSEIの成長相場の動向:[株式4分割:(2018/6/27)分割比率修正済] 2010/12/30 (終値_338) ・(2010/10/15※最安値_163、2010/12/27最高値_437) ※QVA149第V相開始 2011/12/30 (終値_318) ・(2011/_3/15※最安値_173、2011/_6/30最高値_420) ※ノルレボ承認 2012/12/28 (終値_522) ・(2012/_6/_6※最安値_238、2012/_9/_7最高値_742) ※Seebri欧州・日本承認 2013/12/30 (終値1079) ・(2013/_1/_4※最安値_513、2013/_5/_7最高値1525) ※Ultibro欧州・日本承認 2014/12/30 (終値1093) ・(2014/_4/12※最安値_464、2014/_9/_8最高値1500) ※SOSEI中長期計画発表・野村レポート[成長回収期の入口]ステージへ 2015/12/30 (終値2488) ・(2015/_3/16※最安値_713、2015/12/14最高値2645) ※Heptares[成功の序章ステージ]→※米国承認[次なる飛躍ステージへ]→※提携[上抜け圏へ] 2016/12/30 (終値3363) ・(2016/_1/18※最安値2270、2016/_5/_9最高値6545) ※Allergan[強気相場]→※日々公表解除[強気相場解除]→※[時間軸での調整局面へ] 2017/12/29 (終値2735) ・(2017/_9/_6※最安値2148、2017/_1/_6最高値3645) ※[時間軸調整は順調に推移]→※[振るい場・拾い場へ]→※[拾い場も順調に推移] 2018/12/28 (終値_799) ・(2018/12/25※最安値_748、2018/_1/25最高値3195) ※自社開発PL拡充[悪地合いにて再びの拾い場へ]→※Sosei Heptares始動[拾い場] 2019/_1/_4 (大発会)
BY プロ投資家 0083山師さん@トレード中 (ラクッペ MM1f-sxLP [110.165.199.166])2019/01/04(金) 12:14:02.76ID:N5M22agvM 今日下がるなら死にます。 0084山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/04(金) 12:16:03.76ID:fXexs35I0>>82 おいおいおいおい 俺様はそんじゃそこいらのプロ投資家とは格が違うだよ 一緒にすんじゃねえぞ 0085山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/04(金) 12:32:09.66ID:fXexs35I0 俺の予想は大体当たる しかも先出し もう一度いう 今日は前場高値877円を抜けることはない 0086山師さん@トレード中 (ラクッペ MM1f-sxLP [110.165.199.166])2019/01/04(金) 12:50:20.90ID:N5M22agvM 売り爆弾投下 0087山師さん@トレード中 (オッペケ Srcf-mo7v [126.200.126.57])2019/01/04(金) 12:50:27.88ID:EZYm1F/Sr また午後買い手不在のクソ垂れ上髭チャート 0088山師さん@トレード中 (ワッチョイW 0bdb-O44v [218.228.130.47])2019/01/04(金) 12:52:21.39ID:hHcjK8aE0>>86 空売り外資を舐めんなよ 0089山師さん@トレード中 (スップ Sdc2-czLK [1.66.102.156])2019/01/04(金) 12:53:31.82ID:cdoEbdaBd 今年最後の陽線 0090山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/04(金) 13:02:37.15ID:fXexs35I0 お前らは何も分かっていない 下がったら買いなんだわ 恐らくだが、年内2000〜3000円位までは上がるはず いままで二年半も下がり続けてきたらから嘘だと思うだろ? 間違いねえから 0091山師さん@トレード中 (ラクッペ MM1f-sxLP [110.165.199.166])2019/01/04(金) 13:06:46.53ID:N5M22agvM ここからマイナス引けなら死にます。 0092山師さん@トレード中 (スップ Sdc2-czLK [1.66.102.156])2019/01/04(金) 13:17:46.06ID:cdoEbdaBd マイテンしそうww 0093山師さん@トレード中 (ワッチョイW 2ff1-yq5T [222.5.216.180])2019/01/04(金) 13:24:35.76ID:0JQv59TN0 もう金ねんだわ 0094山師さん@トレード中 (ワッチョイ 02be-6YBr [125.0.160.208])2019/01/04(金) 13:25:06.93ID:cVB1S3Ve0 ちょっと笑った 0095山師さん@トレード中 (ワッチョイ 5bc3-Et/P [202.124.48.6 [上級国民]])2019/01/04(金) 15:00:19.90ID:0W2Z7ElX0 Heptares Zurich update: ・・・ ※Nature Structural & Molecular Biology: "High-Resolution Crystal Structure of Parathyroid Hormone 1 Receptor in Complex with a Peptide Agonist": (Department of Biochemistry, University of Zurich; Heptares Zurich; Sosei Heptares; PSI). (11/19 Published) ・Parathyroid hormone 1 receptor (PTH1R) is a class B multidomain G-protein-coupled receptor (GPCR) that controls calcium homeostasis. ・Two endogenous peptide ligands, parathyroid hormone (PTH) and parathyroid hormone–related protein (PTHrP), activate the receptor, and their analogs teriparatide and abaloparatide are used in the clinic to increase bone formation as an effective yet costly treatment for osteoporosis. ・Activation of PTH1R involves binding of the peptide ligand to the receptor extracellular domain (ECD) and transmembrane domain (TMD), a hallmark of class B GPCRs. ・Here, we present the crystal structure of human PTH1R in complex with a peptide agonist at 2.5-Å resolution, allowing us to delineate the agonist binding mode for this receptor and revealing molecular details within conserved structural motifs that are critical for class B receptor function. ・Thus, this study provides structural insight into the function of PTH1R and extends our understanding of this therapeutically important class of GPCRs. ※University of Zurich (UZH) News Release:"From Receptor Structure to New Osteoporosis Drugs". (11/19) ・Researchers at the University of Zurich have determined the three-dimensional structure of a receptor that controls the release of calcium from bones. ・The receptor is now one of the main candidates for developing new drugs to treat osteoporosis. ・The study also involved researchers from the British company Heptares and Heptares Therapeutics Zurich, which grew out of a UZH spin-off co-founded by Andreas Pluckthun. ※Fiona Marshall: "Congratulations to Andreas and his Team and the Team at Heptares for the PTH Receptor Structure". (11/20) ※RCSB Protein Data Bank (PDB): "High Resolution Crystal Structure of Parathyroid Hormone 1 Receptor in Complex with a Peptide Agonist: 6FJ3". (11/21 Released) ※Sosei Heptares: "Our Joint Publication with the University of Zurich on the Structure of the PTH Receptor is Now Available." (11/21) ↓ 0096山師さん@トレード中 (ワッチョイ 5bc3-Et/P [202.124.48.6 [上級国民]])2019/01/04(金) 15:00:44.97ID:0W2Z7ElX0 ※Nature Communications: "Crystal Structures of the Human Neurokinin 1 Receptor in Complex with Clinically Used Antagonists": (Department of Biochemistry, University of Zurich; Heptares Zurich; Sosei Heptares; PSI). (2019/1/3 Published) ・Jendrik Schoppe, Janosch Ehrenmann, Christoph Klenk, Prakash Rucktooa, Marco Schutz, Andrew S. Dore & Andreas Pluckthun. ・Nature Communicationsvolume 10, Article number: 17 (2019). Abstract: ・Neurokinins (or tachykinins) are peptides that modulate a wide variety of human physiology through the neurokinin G protein-coupled receptor family, implicated in a diverse array of pathological processes. ・Here we report high-resolution crystal structures of the human NK1 receptor (NK1R) bound to two small-molecule antagonist therapeutics – aprepitant and netupitant and the progenitor antagonist CP-99,994. ・The structures reveal the detailed interactions between clinically approved antagonists and NK1R, ・which induce a distinct receptor conformation resulting in an interhelical hydrogen-bond network that cross-links the extracellular ends of helices V and VI. ・Furthermore, the high-resolution details of NK1R bound to netupitant establish a structural rationale for the lack of basal activity in NK1R. ・Taken together, these co-structures provide a comprehensive structural basis of NK1R antagonism and will facilitate the design of new therapeutics targeting the neurokinin receptor family. Data availability: ・Atomic coordinates and structure factors have been deposited in the Protein Data Bank (PDB) under accession codes 6HLL, 6HLO and 6HLP for the CP-99,994-, aprepitant- and netupitant-bound NK1R, respectively. Competing interests: ・Prakash Rucktooa (Sosei Heptares, Steinmetz Building), Marco Schutz (Heptares Zurich), and Andrew S. Dore (Sosei Heptares, Steinmetz Building) are employees of Sosei Heptares, a company with activities in the GPCR field. ・All other authors declare no competing interests. https://www.nature.com/articles/s41467-018-07939-8.pdf0097山師さん@トレード中 (ワッチョイ eb0f-xhm2 [122.17.221.67])2019/01/04(金) 15:11:14.19ID:fXexs35I0 直近5営業分のローソク足を終値ベースで全て包んだぜ これ相当強いぞ 0098山師さん@トレード中 (ワッチョイ 5bc3-Et/P [202.124.48.6 [上級国民]])2019/01/04(金) 15:20:30.97ID:0W2Z7ElX0 ※モーニングスター:マザーズ指数反発、小型株に資金流入で逆行高=新興市場・4日。(1/4 15:12) マザーズ指数が反発。東証1部市場が一時700円を超す大幅安となる中、小型株には波乱商状となる大型の輸出株を避けたアクティブな資金が流入した。 オンコリスバイオファーマ、ブライトパス・バイオなどバイオ株が人気で、そーせいグループやサンバイオも堅調。 エクストリームやジェネレーションパスも買われた。ジャスダックは軟調だが、サン電子や日本エマージェンシーアシスタンスは買われた。 0099山師さん@トレード中 (スップ Sdc2-czLK [1.66.102.156])2019/01/04(金) 16:47:45.80ID:cdoEbdaBd そーせいさん苦しんでる死ね 0100山師さん@トレード中 (ワッチョイ 5bc3-Et/P [202.124.48.6 [上級国民]])2019/01/04(金) 17:30:06.83ID:0W2Z7ElX0 ※フィスコ:[マザーズ市況] マザーズ指数は大幅反発、押し目買いの動きが活発化、ブライトパスがストップ高。(1/4 16:29) 本日のマザーズ指数は大幅反発となった。3日のNYダウが660ドル超の下落と下押したほか、日経平均も節目の20000円を大きく下回ったことからセンチメント悪化が意識され、リスク回避の動きからマザーズ市場にも朝方から売りが先行した。 その後は、円相場で円高進行が一服するなか、アジア市場の下げ止まりなどを背景に個人投資家による押し目買いの動きも活発化し、後場にかけてマザーズ指数はプラスに転じた。 バイオ株中心に上げ幅を拡大させるなか、大引けにかけてマザーズ指数は一段高となった。なお、売買代金は概算で808.69億円。騰落数は、値上がり139銘柄、値下がり127銘柄、変わらず8銘柄となった。 値上がり率上位銘柄では、ブライトパス・バイオがストップ高水準まで買い進まれたほか、旅工房やアンジェスなどが20%高となった。 売買代金上位では、オンコリスバイオファーマのほか、サンバイオ、エクストリーム、UUUM、そーせい、ジェネレーションパスが上昇。